Please find enclosed herewith outcome of the Board Meeting held today i.e. 17th December, 2025 in terms of Regulations 30 of SEBI (LODR)Regulations, 2015 for your Information.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.2 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Royal Sense Ltd's board, at its meeting on 17th December 2025, approved the allotment of 3,92,000 warrants convertible into equity shares to its promoter and non-promoter group on a preferential basis. Each warrant is priced at Rs. 251 (face value Rs. 10, premium Rs. 241), taking the total issue size to about Rs. 9.84 crore. The company has already received 25% of the consideration upfront, with the balance payable at the time of conversion within 18 months. The largest share, 2,50,000 warrants, is going to Managing Director Rishabh Arora, while the remaining 1,42,000 warrants are spread across 21 non-promoter individuals. The paid-up share capital will not rise immediately and will increase only when these warrants are actually converted into equity shares.
Existing shareholders face potential dilution over the next 18 months once the warrants convert into equity shares. On the positive side, the strong participation by the promoter signals confidence in the company's growth, and the company is raising fresh capital without immediate equity dilution.